GLPwatch

GLP1R-imaging in Hypoglycemia

NCT03182192 · Unknown status

Last updated 2026-05-28

This clinical trial is testing whether a special imaging scan using 68Ga-exendin can detect changes in the pancreas of people who experience low blood sugar.

Status Unknown status The sponsor has not confirmed the status recently.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Non-randomized, open-label (no blinding) basic-science study
Participants 12 people Planned (estimated).
Who can join Ages 18+ · all sexes Healthy volunteers accepted.
Timeline Started 2016-04 · est. completion 2024-07
Where 2 sites · Netherlands

What this study is testing ClinicalTrials.gov NCT03182192 ↗

Description as written by the study sponsor.

Hyperinsulinemic hypoglycemia (HH) is a rare complication that occurs 1 to 5 years after gastric bypass surgery. The underlying mechanism of this complication is not yet completely understood. Changes in hormone levels, such as GLP1 after RYGB, nesidioblastosis or an increase in the number of beta cells may be one of the underlying causes. However, several study results are conflicting and it is hypothesized that the patient population with HH after RYGB is heterogeneous and several underlying causes may be present. In order to differentiate between hyperfunction with normal beta cell mass and a general or localized increase in beta cell mass we aim to compare quantitative 68Ga-exendin-4 PET imaging of the pancreas between patients with and without HH after RYGB. Thereby, investigators aim to increase the insight in the underlying mechanism of HH after RYGB. If different underlying causes can be diagnosed, treatment for HH can be optimized for patients.

Treatments tested

Main thing measuredUptake of 68Ga-exendin in the pancreas of patients
SponsorRadboud University Medical Center
Conditions studiedHypoglycemia
GLP-1 drugs —

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03182192 ↗